Prevalence and Thrombotic Risk Assessment of Anti-β2 Glycoprotein I Domain I Antibodies: A Systematic Review

Abstract Background To date, the exact prevalence of anti-β2 glycoprotein I domain I (anti-β2GPI-DI) antibodies in patients with antiphospholipid syndrome (APS) and their role when assessing thrombosis risk is uncertain. Objectives To estimate the prevalence of anti-β2GPI-DI in patients with APS and to determine whether anti-β2GPI-DI-positive individuals are at greater risk of thrombosis, as compared with individuals without anti-β2GPI-DI, by systematically reviewing the literature. Methods A detailed literature search was applied a priori to Ovid MEDLINE In-Process and Other Non-Indexed Citation 1986 to present and to abstracts from the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP ) Annual Meetings (2011–2015). Results A total of 11 studies, including 1,585 patients, were analyzed. Patients were distributed as follow: 1,218 patients APS (45.4% anti-β2GPI-DI-positive; in more detail: 504 primary APS [55.4% anti-β2GPI-DI-positive], 192 secondary APS [43.2% anti-β2GPI-DI-positive], and 522 not specified), 318 with systemic lupus erythematosus (SLE; 26.7% anti-β2GPI-DI-positive), 49 asymptomatic carriers of antiphospholipid antibodies (aPL) (30.6% anti-β2GPI-DI-positive), and 1,859 healthy controls. When considering the five studies eligible for thrombotic risk assessment, four studies found a significant association of anti-β2GPI-DI-positivity with thrombotic events, whereas one study found no predictive correlation with thrombosis (overall odds ratio [OR] for pooled data: 1.99; 95% confidence interval [CI]: 1.52–2.6; p < 0.0001). Conclusion We report an overall estimated median prevalence of anti-β2GPI-DI antibodies of 44.3% in patients with APS and/or SLE and a significantly higher prevalence among patients with APS compared with SLE alone. Anti-β2GPI-DI antibodies might represent a promising tool when assessing thrombotic risk in patients with APS.

[1]  M. Beutel,et al.  Distribution of antiphospholipid antibodies in a large population-based German cohort , 2016, Clinical chemistry and laboratory medicine.

[2]  K. Devreese,et al.  Role of anti‐domain 1‐ß2glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome: reply , 2016, Journal of thrombosis and haemostasis : JTH.

[3]  S. Baldovino,et al.  Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay , 2016, Clinical and Molecular Allergy.

[4]  M. Khamashta,et al.  Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome , 2016, Lupus.

[5]  P. Meroni.  Anti-beta-2 glycoprotein I epitope specificity: from experimental models to diagnostic tools , 2016, Lupus.

[6]  C. Demetriou,et al.  The association between IgG and IgM antibodies against cardiolipin, β2-glycoprotein I and Domain I of β2-glycoprotein I with disease profile in patients with multiple sclerosis. , 2016, Molecular immunology.

[7]  G. Steiner,et al.  From autoantibody research to standardized diagnostic assays in the management of human diseases – report of the 12th Dresden Symposium on Autoantibodies , 2016, Lupus.

[8]  D. Isenberg,et al.  Measuring IgA Anti-β2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome , 2016, PloS one.

[9]  M. Mahler,et al.  Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers , 2016, Arthritis Research & Therapy.

[10]  Fengchun Zhang,et al.  Evaluation of the diagnostic potential of antibodies to beta2-glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndrome , 2016, Scientific Reports.

[11]  S. Blankenberg,et al.  Antiphospholipid antibodies in a large population-based cohort: genome-wide associations and effects on monocyte gene expression , 2016, Thrombosis and Haemostasis.

[12]  D. Isenberg,et al.  Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review. , 2015, Rheumatology.

[13]  A. Hoxha,et al.  Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles. , 2015, Thrombosis research.

[14]  P. Simioni,et al.  Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[15]  A. Tincani,et al.  Clinical Characterization of Antiphospholipid Syndrome by Detection of IgG Antibodies Against β2‐Glycoprotein I Domain 1 and Domain 4/5: Ratio of Anti–Domain 1 to Anti–Domain 4/5 As a Useful New Biomarker for Antiphospholipid Syndrome , 2015, Arthritis & rheumatology.

[16]  A. Ruffatti,et al.  Antiphospholipid syndrome: antibodies to Domain 1 of β2‐glycoprotein 1 correctly classify patients at risk , 2015, Journal of thrombosis and haemostasis : JTH.

[17]  N. Ronda,et al.  β2-glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis. , 2014, Journal of autoimmunity.

[18]  M. Khamashta,et al.  Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with ‘seronegative’ antiphospholipid syndrome , 2014, Annals of the rheumatic diseases.

[19]  I. Zegers,et al.  International standards for IgG and IgM anti-β2glycoprotein antibody measurement , 2014, Lupus.

[20]  M. Cieśla,et al.  IgA Antiphospholipid Antibodies and Anti-Domain 1 of Beta 2 Glycoprotein 1 Antibodies are Associated with Livedo Reticularis and Heart Valve Disease in Antiphospholipid Syndrome. , 2014, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[21]  D. Sblattero,et al.  A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. , 2014, Blood.

[22]  M. Mahler,et al.  Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[23]  William W. Cohen,et al.  Contribution of anti-β2glycoprotein I IgA antibodies to the diagnosis of anti-phospholipid syndrome: potential interest of target domains to discriminate thrombotic and non-thrombotic patients. , 2014, Rheumatology.

[24]  P. Meroni,et al.  New Tests to Detect Antiphospholipid Antibodies: Anti-Domain I Beta-2-Glycoprotein-I Antibodies , 2014, Current Rheumatology Reports.

[25]  J. Rand,et al.  Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I , 2013, Lupus.

[26]  S. Pierangeli,et al.  Anti‐β2‐glycoprotein I antibodies , 2013, Annals of the New York Academy of Sciences.

[27]  M. Khamashta,et al.  Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. , 2012, Autoimmunity reviews.

[28]  A. Arslan,et al.  Resistance to annexin A5 anticoagulant activity in women with histories for obstetric antiphospholipid syndrome. , 2011, American journal of obstetrics and gynecology.

[29]  P. Meroni,et al.  Pathogenesis of antiphospholipid syndrome: understanding the antibodies , 2011, Nature Reviews Rheumatology.

[30]  P. Groot,et al.  Autoantibodies Directed Against Domain I of Beta2-Glycoprotein I , 2011 .

[31]  Sreeram V Ramagopalan,et al.  Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study , 2011, BMC medicine.

[32]  P. D. de Groot,et al.  Autoantibodies Directed Against Domain I of Beta2-Glycoprotein I , 2010, Current rheumatology reports.

[33]  A. Tincani,et al.  Anti-β2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their ‘innocent’ profile? , 2010, Annals of the rheumatic diseases.

[34]  P. D. de Groot,et al.  The association between circulating antibodies against domain I of beta2‐glycoprotein I and thrombosis: an international multicenter study , 2009, Journal of thrombosis and haemostasis : JTH.

[35]  D. Isenberg,et al.  In vivo inhibition of antiphospholipid antibody‐induced pathogenicity utilizing the antigenic target peptide domain I of β2‐glycoprotein I: proof of concept , 2009, Journal of thrombosis and haemostasis : JTH.

[36]  P. D. de Groot,et al.  Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. , 2007, Blood.

[37]  P. D. de Groot,et al.  IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. , 2005, Blood.

[38]  T. Barbui,et al.  Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. , 2003, Blood.

[39]  T. Barbui,et al.  Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. , 2003, Blood.

[40]  T. Kveder,et al.  Anti‐β2‐glycoprotein I antibodies in children with atopic dermatitis , 2002 .

[41]  S. Reddel,et al.  Epitope studies with anti-beta 2-glycoprotein I antibodies from autoantibody and immunized sources. , 2000, Journal of autoimmunity.

[42]  G. M. Iverson,et al.  Anti-β2 glycoprotein I (β2GPI) autoantibodies recognize an epitope on the first domain of β2GPI , 1998 .

[43]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[44]  Chan Jun-mi,et al.  International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome(APS) , 2008 .

[45]  T. Kveder,et al.  Anti-beta(2)-glycoprotein I antibodies in children with atopic dermatitis. , 2002, International immunology.

[46]  G. M. Iverson,et al.  Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. , 1998, Proceedings of the National Academy of Sciences of the United States of America.